JackLeckerman organizes global summits, strategic conferences, open forums and professional trainings.
Joined February 2017
- Tweets4.7K
- Following699
- Followers156
- Likes323
Get practical advice at #BiosimilarsLatAm #Mexico2026
Book a FREE 20-minute 1-on-1 consultation with experts in:
• Regulatory strategy
• GMP certification
• LATAM market access
• Pharmacovigilance
📅 Nov 18–19 | CDMX
Details: jackleckerman.com/events/bio…
¿Cómo será la aprobación de biosimilares en 2030?
Únete a Francisco Domingo en nuestro webinar sobre la evolución de los requisitos regulatorios y lo que los fabricantes deberían preparar desde hoy.
Inscripción: us06web.zoom.us/webinar/regi…
🔭 What will biosimilar approval look like in 2030?
Join Francisco Domingo for our online webinar exploring the future of biosimilar regulatory requirements — and what manufacturers should prepare for today.
Free Register: us06web.zoom.us/webinar/regi…
🌎 ¿Cómo avanzar hacia una mayor armonización regulatoria de los biosimilares en Latinoamérica?
Acompáñanos en nuestro webinar preparatorio:
📅 6 nov. 2026
🕘 9 a. m. CDMX
🎙️ Expertos de @ANMATsalud
👉 Regístrate: us06web.zoom.us/webinar/regi…
#BiosimilarsLatAm #Biosimilares
🌎 One region, multiple pathways. How can #biosimilar registration become more harmonized across LATAM?
Join our free preparatory #webinar with four @ANMATsalud speakers on Nov 6.
🕒 12 PM Argentina/São Paulo | 4 PM Spain | 9 AM Mexico City
🔗 us06web.zoom.us/webinar/regi…
Join the biosimilars community at #BiosimilarsLatAm – Mexico 2026!
Two days of regulatory insights, manufacturing innovation, market access discussions and Business Meetings.
Members of our Strategic Partners can request an exclusive 10% registration discount.
📅 Nov 18–19 | Mexico City
Register: jackleckerman.com/events/reg…
Susana Guitar, Chairwoman of #BiosimilarsLatAm – #Mexico2026, join the forum’s 10th Edition!
📅 Nov 18–19 | 📍 Mexico City
Two days of industry insights, regulatory discussions, business meetings and networking.
Be part of the conversation.
Register: jackleckerman.com/events/reg…
The right conversation can open a new business opportunity.
#BiosimilarsLatAm – #Mexico2026 is designed to bring pharmaceutical decision-makers, manufacturers, regulators and industry partners into the same conversation.
Beyond the conference sessions, pre-scheduled 20-minute business meetings offer a structured way to connect with relevant professionals and explore potential collaborations.
Make the connections that move the industry forward.
🔗 jackleckerman.com/events/reg…
#StrategicPartnerships
How can continuous improvement enhance particulate control in pre-fillable syringes for biosimilars?
#BiosimilarsLatAm, Philippe Lauwers, Terumo Pharmaceutical Solutions, case study demonstrating how a holistic approach to manufacturing quality can deliver measurable results.
“Kaizen in Action: A Holistic Approach to Particulate Reduction in Pre-fillable Syringes (PFSs) for Biosimilars,” Philippe will explore how Terumo Pharmaceutical Solutions addressed visible particulate contamination in ready-to-use polymer syringes through continuous improvement.
📍 Join us on November 18–19, 2026, at Camino Real Polanco, Mexico City, to explore manufacturing innovation, quality and the evolving biosimilars landscape across Latin America.
🔗 jackleckerman.com/events/reg…
#TerumoPharmaceuticalSolutionsDivision #DrugDelivery #PatientExperience
As a sponsor of Biosimilars LatAm – Mexico 2026, Terumo Medical Care Solutions brings expertise in innovative medical devices, injectable drug delivery solutions and integrated CDMO services, including sterile fill-finish in polymer pre-fillable syringes and glass vials.
This case study highlights how robust manufacturing processes and effective contamination-control strategies can help meet the stringent quality requirements of ophthalmic drugs, where the use of prefilled syringes continues to grow.
The approach combined enhanced cleaning practices, low-particulate materials, static electricity management, operator training and analytical method optimization.
📉 The result: a 97% reduction in visible particulate levels over 18 months.
How can analytical comparability accelerate biosimilar development?
#BiosimilarsLatAm #Mexico2026, Kathya Rashida of Cuba’s CIM will present its experience with 2C12, a pembrolizumab biosimilar candidate.
🤝 #CIM is a Sponsor.
📅 Nov 18–19 | Mexico City
Este foro reúne a líderes de la industria farmacéutica, fabricantes, autoridades regulatorias y otros actores clave para analizar los cambios que están configurando el mercado de los biosimilares en #latam.
jackleckerman.com/events/age…
#BiosimilarsLatAm #Mexico2026 #Biosimilars
How could evolving evidence on interchangeability and switching help shape biosimilar development? Join ANVISA 🇧🇷 , ANMAT 🇦🇷 and CECMED 🇨🇺 perspectives at #BiosimilarsLatAm - #Mexico2026, Nov 18–19.
🔗 Download the agenda: jackleckerman.com/events/age…
